Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Key Inclusion Criteria:

Histologically confirmed diagnosis of relapsed or refractory cHL

Relapsed cHL (disease progression after PR or CR to the most recent therapy) or refractory cHL (failure to achieve PR or CR to most recent therapy). Participants will be allocated to one of two cohorts based on the following criteria:

Cohort 1: Relapsed or refractory to prior autologous hematopoietic stem cell transplant (HSCT)

Has failed to achieve a response or progressed after autologous HSCT
Is not a candidate for additional autologous or allogeneic HSCT

Cohort 2: Relapsed or refractory to salvage chemotherapy, and has not received prior autologous or allogeneic HSCT

Is not a candidate for autologous or allogeneic HSCT
Has received at least 1 prior systemic regimen for cHL
Measurable disease defined as ≥ 1 2-[18F] fluoro-2-deoxy-D-glucose (FDG)-avid nodal lesion that is > 1.5 cm in the longest diameter, or ≥ 1 FDG-avid extra-nodal lesion (eg, hepatic nodules) that is > 1 cm in the longest diameter
Eastern Cancer Oncology Group (ECOG) performance status of 0 or 1

Key Exclusion Criteria:

Nodular lymphocyte-predominant Hodgkin lymphoma or gray zone lymphoma
Prior allogeneic hematopoietic stem cell transplantation
Prior therapy targeting PD-1 , PD-L1,PD-L2, or CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) pathways
Active autoimmune disease or history of autoimmune disease that may relapse

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.